A Phase 2, Randomized, Double-blind, Placebo Controlled, Single Dose-level, Proof-of-concept Study Evaluating FP-101 for the Treatment of Vasomotor Symptoms in Postmenopausal Women
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2019
Price : $35 *
At a glance
- Drugs FP-101 (Primary)
- Indications Hot flashes
- Focus Proof of concept; Therapeutic Use
- Sponsors Fervent Pharmaceuticals
- 14 Mar 2019 According to the Fervent Pharmaceuticals media release, company announced positive proof of concept results from this trial.
- 31 Oct 2018 Status changed from recruiting to completed.
- 04 Apr 2018 Status changed from not yet recruiting to recruiting.